Bloomberg Stock Movers

2026-06-29 · Hosted by — · Bloomberg / iHeartMedia

Executive Summary

Bloomberg’s Nathan Hager and Dan Curtis run a pre-market roundup of Monday’s movers. The headline is Comcast surging ~22% on plans to spin off NBCUniversal and Sky into a separately traded company, the latest step in its media restructuring. Verizon dips slightly on a new international joint venture with BT that will trigger a $700–800 million quarterly loss, BioLife Solutions climbs on takeover interest from Repligen, and SpaceX ticks up ~2% as it nears NASDAQ-100 inclusion (July 7) and joins FTSE Russell indexes today — buying that Bloomberg Intelligence estimates at ~$5.4 billion.

Key Stories & Changes

1. Movers of the Morning

  • CMCSA: Comcast — +22% (pre-market) — Spinning off NBCUniversal & Sky into a separate public company

  • VZ: Verizon — -~0.5% (pre-market) — BT international JV; $700–800M quarterly loss from accounting

  • BLFS: BioLife Solutions — +~1% (pre-market) — Takeover interest from Repligen; +30% over the past year

  • SPACEX: SpaceX — +~2% (pre-market) — Nears NASDAQ-100 inclusion July 7; joins Russell indexes today

2. Comcast NBCUniversal Spinoff

  • NBCUniversal and Sky to be spun off into a publicly traded company called NBCUniversal

  • Separation expected complete in ~one year; shareholders will own shares of both

  • Comcast retains a ~20% stake for up to a year, then divests slowly

  • Follows the earlier spinoff of cable-network unit Versant (CNBC, MSNBC/MS Now)

3. Verizon–BT Joint Venture

  • JV combines the two companies’ international businesses; combined revenue ~$4 billion

  • Verizon to record a $700–800 million quarterly loss tied to deal accounting (assets classified held-for-sale)

  • Verizon to pay $625 million cash to the JV for distribution to BT; BT cut its guidance after the deal

4. BioLife Solutions Takeover Interest

  • BioLife (cell-therapy tools/services) drew takeover interest including from Repligen

  • Shares +30% over the past year amid sector consolidation and excitement over innovative treatments

  • Unclear how BioLife plans to respond

5. SpaceX Index Inclusion

  • Joins the NASDAQ 100 before the open on July 7; a ~$2 trillion market cap would make it the seventh-largest member

  • NASDAQ adjusted rules so one-month-old stocks can qualify — adding it earlier than usual (largely priced in)

  • Also joins FTSE Russell indexes (including Russell 1000) today; Bloomberg Intelligence estimates ~$5.4 billion of buying across both additions

1. Media Conglomerates Breaking Up

Comcast’s NBCUniversal/Sky spinoff, following its earlier Versant separation, underscores a continuing trend of legacy media conglomerates unbundling content and distribution to unlock value — a structural reshaping rewarded with a 22% pre-market pop.

2. Index Inclusion as a Mechanical Catalyst

SpaceX’s pre-market gain is driven less by fundamentals than by forced passive buying — ~$5.4B estimated across its Russell and NASDAQ-100 additions. The episode highlights how accelerated index-rule changes turn inclusion timing into a near-term price catalyst.

3. Ongoing Biotech/Healthcare Consolidation

BioLife’s takeover interest from Repligen fits a year of “large consolidation” in cell-therapy tools, consistent with the broader healthcare M&A wave lifting the sector. —-

Sentiment Analysis

Overall Market Sentiment: Risk-On

A constructive pre-market tone with deal-driven gains and a general “risk-on tune” lifting SpaceX.

Risk Factors Highlighted

Verizon near-term loss: A $700–800M quarterly hit and BT’s guidance cut signal short-term pain from the JV.

SpaceX inclusion already priced: Much of the index-inclusion buying is “already baked into the price,” limiting upside.

BioLife deal uncertainty: It is unclear whether BioLife will accept or resist takeover interest.

Comcast execution/timeline: The spinoff takes ~one year and a gradual stake wind-down to complete.

This episode was covered in today’s The Market Signal — 2026-06-29, a cross-source synthesis of multiple podcast reports.

Keep Reading